控制Helicobacter pylori的工程益生菌分泌有选择性的引导抗微生物
Ankan Choudhury1, Patrick S Ortiz1, Mikaeel Young1
1Department of Biology, Baylor University , Waco, Texas, USA.
Microbiology spectrum
|September 15, 2023
概括
工程益生菌提供向的抗微生物来消除Helicobacter pylori,这是胃癌的关键原因. 这种方法为抗生素提供了一种选择性,可持续的替代方案,用于控制感染和预防癌症.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 生物技术是生物技术.
背景情况:
- 杆菌感染是胃癌的主要驱动因素,需要新的治疗策略.
- 目前针对H. pylori的抗生素治疗可以导致失生症和抗生素耐药性.
- 控制H. pylori提供了预防胃癌的重要机会.
研究的目的:
- 开发针对H.pylori的高度选择性的抗菌剂.
- 为了设计益生菌,以便有针对性地输送这些药物.
- 评估这些工程益生菌的疗效和安全性,在体外和体内.
主要方法:
- 一种H.pylori结合 (MM1) 与宽谱抗菌 (AMP) 的融合,以创建受引导的AMP (gAMP).
- 设计乳球菌来分泌gAMP.
- 在H. pylori感染小鼠的体外共同培养试验和体内口腔试验.
主要成果:
- gAMP益生菌表现出高特异性,保留了对H. pylori的毒性,同时显著降低了对非向细菌的毒性.
- 在5天内,gAMP益生菌有效地消除了小鼠中的H. pylori,超过了抗生素治疗.
- 用gAMP益生菌治疗导致胃微生物多样性的显著恢复.
结论:
- 产生gAMP的工程益生菌是一种有希望的,高度选择性的治疗和预防策略,用于对抗H. pylori.
- 这种方法为抗生素提供了一种可持续的替代方案,可以缓解抗生素失效和抗生素耐药性.
- 模块化gAMP技术可以适应针对其他病原体,并有可能开发尾酒来防止耐药性.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
442
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
442
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
463
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
463
Peptic Ulcer Disease IV: Management
110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
460
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
460
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
632
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
632
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
511
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
511


